Table 1 |
||||||
|
Correlation of EGFR and pEGFR expression with clinicopathological parameters, ER/PR, c-erbB-2, pAkt, uPAR, MMP-14 and VEGFR-1/Flt-1 |
||||||
| Parameters |
Total |
EGFR |
PEGFR |
|||
|
|
||||||
| n (%) |
P |
n (%) |
P |
|||
|
|
||||||
| Menopausal status |
Premenopausal |
50 |
5 (10.0) |
NS |
13 (26.0) |
NS |
| Postmenopausal |
104 |
13 (12.5) |
42 (40.4) |
|||
| Histological type |
Ductal |
121 |
15 (12.4) |
NS |
41 (33.9) |
NS |
| Lobular |
32 |
3 (9.4) |
13 (40.6) |
|||
| Histological grade |
1 |
23 |
1 (4.3) |
NS |
7 (30.4) |
NS |
| 2 |
90 |
11 (12.2) |
35 (38.9) |
|||
| 3 |
36 |
6 (16.7) |
11 (30.6) |
|||
| Nuclear grade |
1 |
53 |
1 (1.9) |
0.001 |
18 (34.0) |
NS |
| 2 |
53 |
5 (9.4) |
23 (43.4) |
|||
| 3 |
47 |
12 (25.5) |
13 (27.7) |
|||
| Tumour size |
<2 cm |
37 |
2 (5.4) |
NS |
13 (35.1) |
NS |
| 2 to 5 cm |
91 |
11 (12.1) |
32 (35.2) |
|||
| >5 cm |
25 |
5 (20.0) |
9 (36.0) |
|||
| Lymph node status |
Noninfiltrated |
61 |
6 (9.8) |
NS |
19 (31.1) |
NS |
| Infiltrated |
91 |
12 (13.2) |
35 (38.5) |
|||
| Stage |
1 |
28 |
2 (7.1) |
NS |
9 (32.1) |
NS |
| 2 |
97 |
12 (12.4) |
33 (34.0) |
|||
| 3 |
27 |
4 (14.8) |
12 (44.4) |
|||
| ER |
Negative |
70 |
14 (20.0) |
0.005 |
20 (28.6) |
NS |
| Positive |
83 |
4 (4.8) |
35 (42.2) |
|||
| PR |
Negative |
78 |
13 (16.7) |
NS |
30 (38.5) |
NS |
| Positive |
75 |
5 (6.7) |
25 (33.3) |
|||
| c-erbB-2 |
Negative(<10) |
60 |
5 (8.3) |
NS |
21 (35.0) |
NS |
| Positive(≥ 10) |
93 |
13 (14.0) |
34 (36.6) |
|||
| pAkt |
Negative (<10) |
49 |
3 (6.1) |
NS |
12 (24.5) |
0.008 |
| Positive (≥ 10) |
72 |
11 (15.3) |
35 (48.6) |
|||
| uPAR |
Negative (<15) |
49 |
9 (18.3) |
NS |
12 (24.5) |
0.049 |
| Positive (≥ 15) |
67 |
6 (9.0) |
29 (43.3) |
|||
| MMP-14 |
Negative (= 0) |
93 |
13 (14.0) |
NS |
28 (30.1) |
0.025 |
| Positive (>0) |
29 |
2 (6.9) |
16 (55.2) |
|||
| VEFGR-1/Flt-1 |
Negative (<30) |
40 |
5 (12.5) |
NS |
9 (22.5) |
0.016 |
| Positive (≥ 30) |
72 |
9 (12.5) |
33 (45.8) |
|||
|
|
||||||
|
EGFR, epidermal growth factor receptor; ER, oestrogen receptor; MMP, matrix metalloproteinase; NS, not significant; pAkt, phosphorylated Akt; pEGFR, phosphorylated epidermal growth factor receptor; PR, progesterone receptor; uPAR, urokinase plasminogen activator receptor; VEGFR, vascular endothelial growth factor receptor. |
||||||
|
Magkou et al. Breast Cancer Research 2008 10:R49 doi:10.1186/bcr2103 |
||||||
